IRIS
PATRIARCA, Francesca
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.542
EU - Europa 3.235
AS - Asia 2.985
SA - Sud America 448
AF - Africa 36
Continente sconosciuto - Info sul continente non disponibili 14
OC - Oceania 5
Totale 18.265
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.444
SG - Singapore 1.273
UA - Ucraina 1.056
CN - Cina 748
HK - Hong Kong 550
DE - Germania 536
BR - Brasile 403
IT - Italia 375
FI - Finlandia 345
RU - Federazione Russa 281
SE - Svezia 228
IE - Irlanda 199
VN - Vietnam 93
TR - Turchia 86
GB - Regno Unito 78
CA - Canada 71
KR - Corea 70
IN - India 50
AT - Austria 26
BD - Bangladesh 23
IR - Iran 21
BE - Belgio 20
FR - Francia 20
NL - Olanda 19
CO - Colombia 16
AR - Argentina 15
EU - Europa 14
MX - Messico 14
IQ - Iraq 12
PL - Polonia 12
CZ - Repubblica Ceca 11
JP - Giappone 10
TG - Togo 8
ZA - Sudafrica 7
AZ - Azerbaigian 6
SA - Arabia Saudita 6
AE - Emirati Arabi Uniti 5
AU - Australia 5
MA - Marocco 5
RS - Serbia 5
VE - Venezuela 5
EG - Egitto 4
JM - Giamaica 4
PK - Pakistan 4
PY - Paraguay 4
RO - Romania 4
EC - Ecuador 3
ES - Italia 3
IL - Israele 3
KE - Kenya 3
KG - Kirghizistan 3
NP - Nepal 3
OM - Oman 3
PA - Panama 3
SN - Senegal 3
UZ - Uzbekistan 3
AL - Albania 2
BB - Barbados 2
BG - Bulgaria 2
CH - Svizzera 2
DZ - Algeria 2
HN - Honduras 2
ID - Indonesia 2
JO - Giordania 2
LV - Lettonia 2
PE - Perù 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
BH - Bahrain 1
BY - Bielorussia 1
DK - Danimarca 1
EE - Estonia 1
HU - Ungheria 1
KH - Cambogia 1
KZ - Kazakistan 1
LB - Libano 1
LK - Sri Lanka 1
LT - Lituania 1
LU - Lussemburgo 1
MD - Moldavia 1
ML - Mali 1
NG - Nigeria 1
PS - Palestinian Territory 1
PT - Portogallo 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TN - Tunisia 1
Totale 18.265
Salva come PNG Salva come JPEG
Città #
Fairfield 1.589
Woodbridge 1.361
Houston 994
Ann Arbor 893
Ashburn 748
Jacksonville 701
Wilmington 644
Seattle 636
Singapore 629
Chandler 569
Hong Kong 550
Cambridge 509
Dearborn 454
Beijing 389
Boardman 268
Princeton 211
Dublin 198
Udine 146
San Diego 99
Hefei 89
Izmir 78
Dong Ket 69
Seoul 67
Munich 66
Ogden 51
Des Moines 44
Norwalk 43
Ottawa 40
Nuremberg 34
New York 30
São Paulo 30
Kunming 26
Nanjing 26
Turku 23
Los Angeles 21
Redmond 19
Trieste 19
Brussels 18
Dallas 18
Guangzhou 18
Nanchang 15
Rome 15
Frankfurt am Main 14
Rio de Janeiro 14
Toronto 14
Hyderabad 13
Santa Clara 13
Simi Valley 13
Bogotá 12
Düsseldorf 12
Duino-Aurisina 11
Lappeenranta 11
Shenyang 11
Vienna 11
Chengdu 10
Council Bluffs 10
Hanoi 10
Leawood 10
Belo Horizonte 9
Falls Church 9
Fuzhou 9
Montreal 9
Phoenix 9
Porto Alegre 9
Redwood City 9
Shanghai 9
Venezia 9
Washington 9
Boston 8
Brasília 8
Jinan 8
Lomé 8
Warsaw 8
Campinas 7
Dhaka 7
Fayetteville 7
Ho Chi Minh City 7
London 7
Uppsala 7
Wuhan 7
Zhengzhou 7
Amsterdam 6
Andover 6
Atlanta 6
Brooklyn 6
Grafing 6
Helsinki 6
Mumbai 6
San Mateo 6
Baku 5
Belgrade 5
Chicago 5
Chongqing 5
Contagem 5
Curitiba 5
Indiana 5
Johannesburg 5
Lauterbourg 5
Milan 5
Moscow 5
Totale 12.925
Salva come PNG Salva come JPEG
Nome #
Prognostic significance of the detection of tumour cells in peripheral blood stem cell collections in stage II and III breast cancer patients treated with high-dose therapy 251
Combined orthotopic heart transplantation followed by autologous stem cell transplantation in a patient with light chain amyloidosis and isolated cardiac involvement 180
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis 170
The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery 161
Activity of all-trans-retinoic acid in a case of central nervous system extramedullary relapse of acute promyelocytic leukemia 154
The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation 151
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD). 148
Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: study from the Italian Bone Marrow Donor Registry. 147
Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia 147
B-cell immune reconstitution after allogenic stem cell transplantation and its role in the development of chronic graft-versus-host disease 142
Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study 142
Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases 141
Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)” 141
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. 141
Clinical feature and outcome in seven patients wuth hyaline or mixed variant of Castleman’s disease. A single centre experience 140
Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia 137
18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease 136
Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results 135
Long-Term Follow-Up of a Donor versus No-Donor Comparison in Patients with Multiple Myeloma in First Relapse after Failing Autologous Transplantation 131
Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab. 131
Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma. 130
Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: A multicenter retrospective study based on donor availability 129
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma 128
A comparison of allografting with autografting for newly diagnosed myeloma 128
Allogeneic Stem Cell Transplantation for Relapsed/Refractory B Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial including Rituximab in the Reduced-Intensity Conditioning Regimen. 128
Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease 127
Phase II trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib 127
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis 125
Busulfan- or Thiotepa-Based Conditioning in Myelofibrosis: A Phase II Multicenter Randomized Study from the GITMO Group 125
Risk Factors and Outcomes of Infections by Multidrug-Resistant Gram-Negative Bacteria in Patients Undergoing Hematopoietic Stem Cell Transplantation 124
Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe) 122
Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers. 122
Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials 122
Impact of hepatitis C virus infection on clinical features, quality of life and survival of patients with lymphoplasmacytoid lymphoma/immunocytoma 120
CD3+ graft cell count influence on chronic GVHD in haploidentical allogeneic transplantation using post-transplant cyclophosphamide 120
Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. 119
Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura 119
Rituximab for the treatment of type II mixed cryoglobulinemia 118
Bendamustine in relapsed/refractory multiple myeloma: the "real-life" side of the moon. 118
Defibrotide : review on clinical use and future development 117
Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma. 117
Antimicrobial resistance in Gram-negative rods causing bacteremia in hematopoietic stem cell transplant patients: intercontinental prospective study of Infectious Diseases Working Party of the European Bone Marrow Transplantation group 117
Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. 116
Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma. 116
Continuous therapy versus fixed duration of therapy in patients with newly diagnosed multiple myeloma 115
Efficacy and safety of peripheral blood stem cell mobilization and collection: a single-center experience in 190 allogeneic donors. 114
Acute myeloid leukemia following chronic low-dose cyclophosphamide in metastatic breast cancer 112
KERATOCONJUNCTIVITIS TREATMENT WITH AUTOLOGOUS SERUM EYE IN PATIENTS WITH SEVERE CHRONIC GVHD 112
Acute hepatic failure as onset of progressive sclerodermatous chronic graft-versus-host disease after donor lymphocyte infusion. 111
Flow cytometry evaluation of plasma cells contaminating leukapheresis pre- and post- CD34-positive selection- 110
T-cell chimerism and clinical outcome after reduced-intensity conditioning allogeneic stem cell transplantation 110
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. 110
Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study 109
Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis 108
New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment? 108
Intensified full-dose induction therapy (HD-MACHOP+radiotherapy) follwed dy consolidation with BAVC regimen and autologous stem cell transplantation as fron-line therapeutic approach for high risk aggressive non Hodgkin lymphoma 107
Factors affecting outcome of allogeneic stem cell transplantation as salvage in patients with acute myeloid leukemia primary refractory to intensive induction therapy. 107
JAK-2 inhibitors and allogeneic transplant in myelofibrosis 107
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma 106
Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe) 106
Occurrence of multiple myeloma after fludarabine treatment of a chronic lymphocytic leukemia: evidence of a biclonal derivation and clinical response to autologous transplantation 104
Cytokines dysregulation and chronic graft versus host disease after allogeneic haematopoieitc stem cell transplantation with reduced intensity conditioning 103
B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. 103
‘Real-life’ report on the management of chronic GvHD in the gruppo Italiano trapianto midollo osseo (GITMO) 102
Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey in 50 patients 102
Multiple Myeloma: presenting features and survival according to hospital referral 101
Long lasting remission after haploidentical stem cell transplant and pre-emptive donor lymphocyte infusions in a patient with primary refractory Hodgkin lymphoma 101
Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivation 99
Factors predicting outcome after allogeneic transplant in refractory acute myeloid leukemia: a retrospective analysis of Gruppo Italiano Trapianto di Midollo Osseo (GITMO) 99
Sequential study of cytokine and lymphocyte patterns in patients with chronic agraft versus host disease after reduced intensity conditioning allogenic stem cell transplantation 98
FEASIBILITY AND OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS OLDER THAN 60 YEARS WITH POOR RISK ACUTE MYELOID LEUKEMIA 97
Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous: a retrospective study based on the time of HLA typing and donor availability 97
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients 97
Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. 97
Improvement of amyloid-related symptoms after autologous stem cell transplantation in a patient with hepatomegaly, macroglossia and purpura 95
The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation 95
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. 94
Treatment of refractory chronic GVHD with rituximab: a GITMO study 94
Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation. 94
Allogeneic stem cell transplantation and novel therapies: is the treatment paradigm for younger patients with chronic lymphocytic leukemia changing? 94
Pseudomonas pickettii (Biovar VA-II): a rare cause of bacteremias in haematologic patients. 93
Prognostic significance of delayed thrombocytopenia after allogeneic stem cell transplant 93
Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study 92
Qualitative and quantitative polymerase chain reaction monitoring minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation . 92
High dose therapy with stem cell rescue in elderly atients with aggressive poor risk lymphomas: a review of 14 cases. 91
Efficacy of tuemor necrosis factor alfa blockade with infliximab for the treatment of svere steroid-refractory acute graft versus host disease. 91
Autologous transplantation and maintenance therapy in multiple myeloma 91
The CIBMTR score predicts survival of AML patients undergoing allogeneic transplantation with active disease after a myeloablative or reduced intensity conditioning: a retrospective analysis of the Gruppo Italiano Trapianto Di Midollo Osseo. 91
Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial 91
Long-lasting complete remission of hepatitis C virus (HCV) infection and HCV-associated immunocytoma with alpha-interferon treatment 90
Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts 90
Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. 88
Bortezomib plus dexamethasone followed by escalating donor lymphocyte infusions for patients with multiple myeloma relapsing or progressing after allogeneic stem cell transplantation 88
A retrospective analysis of 144 patients with aggressive non-Hodgkin's lymphoma: impact of aurtologoaus stem cell transplantation in first remission on autcome 88
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results. 88
Outcome of allogeneic stem cell transplantation following reduced-intensity conditioninig regimen in patients with idiopathic myelofibrosis: the G.I.T.M.O. Experience. 88
Effect on survival of the development of late-onset non-infectious pulmonary complications after stem cell transplantation. 87
Lenalidomide can induce long-term responses in patients with multiple myeloma relapsing after multiple chemotherapy lines, in particular after allogeneic transplant 87
Kinetics of Th1/Th2 cytokines and lymphocyte subsets to predict chronic GVHD after allo-SCT: results of a prospective study. 87
The genotype of the hepatitis C virus in patients with HCV-related B cell non-Hodgkin's lymphoma. 87
Totale 11.471
Salva come PNG Salva come JPEG
Categoria #
all - tutte 72.609
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 72.609
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.689 50 294 71 393 74 354 234 328 317 104 288 182
2021/20221.611 68 205 85 102 37 69 101 77 15 269 328 255
2022/20231.465 224 73 13 177 142 428 1 103 220 17 32 35
2023/2024489 64 28 10 17 67 53 25 43 81 46 26 29
2024/20253.788 86 285 121 89 295 190 184 240 351 368 551 1.028
2025/2026278 278 0 0 0 0 0 0 0 0 0 0 0
Totale 18.887